RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study https://t.co/3z8qTRcleC
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
Well well
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
In this small retrospective cohort study @TheLancetRheum of patients with #COVID19 and ARDS managed with non-invasive ventilation outside of the ICU, treatment with high-dose anakinra was safe and associated with clinical improvement in 72% of patients. ht
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @azangrillo: Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinf…
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
Éric Topol:1er rapport d'un bloqueur Interleukin-1 pour #COVID19 ) w / ARDS & hyperinflammation https">@TheLancetRheum">https://t.co/d6mKEFuzHN…@TheLancetRheum Seuls 29 patients,pas de témoin, mais signal d'efficacité potentielle avec 21 patients montrant amélioration des b
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
リコンビナントIL-1RaであるアナキンラのCOVID-19に対する治療報告がLancet Rheumatologyに。伊の単施設で中等症~重症患者29例に投与し、非投与群とレトロスペクティブに比較。第21日時点の生存率はアナキンラ投与群で有意に良好だった(p=0.009)。アナキンラは関節リウマチ薬で国内では未承認。
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
Makes sense when given when patients severely ill not too early
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
RT @EricTopol: 1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum On…
Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study - The Lancet Rheumatology https://t.co/fYNnH2Cgqy
1st report of an Interleukin-1 blocker for #COVID19 )w/ ARDS & hyperinflammation https://t.co/hSGBQKGnnS @TheLancetRheum Only 29 patients, no control group, but a signal of potential efficacy with 21 patients showing biomarker improvement and survived
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @Noboru_Hagino: 本当にサイトカインストームなんだったら、抑えるサイトカインはinnate immunity寄りが良いのではないかということで、IL-1RAであるAnakinraのCOVID-19に対する報告。 Kaplan-Meier見ると良さげな雰囲気…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
RT @TheLancetRheum: NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndro…
NEW Research—First study of #anakinra for hospitalised patients with severe #COVID19, acute respiratory distress syndrome, and hyperinflammation finds clinical improvements: findings from 29 adults from one Milan hospital (1/6) https://t.co/dKMda4PtWI #La